{"entity":{"id":"nct02849496","kind":"trial","name":"Olaparib with or without atezolizumab in BRCA-mutant breast cancer","aka":["Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer"],"tldr":"This study compares olaparib alone with olaparib plus atezolizumab in advanced BRCA-mutant breast cancer. It tests adding immune treatment to DNA-repair inhibition, rather than treatment after curative breast surgery.","summary":"This study compares olaparib alone with olaparib plus atezolizumab in advanced BRCA-mutant breast cancer. It tests adding immune treatment to DNA-repair inhibition, rather than treatment after curative breast surgery.\n\nInterventional study registered as NCT02849496, sponsored by National Cancer Institute (NCI). Registry phase: 2. Registry enrollment is 89 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT02849496","url":"https://clinicaltrials.gov/study/NCT02849496"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT02849496"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab","olaparib"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02849496","phase":"2","setting":"BRCA-mutant, HER2-negative unresectable or metastatic breast cancer","sponsor":"National Cancer Institute (NCI)","participation":[{"nct":"NCT02849496","source":"https://clinicaltrials.gov/study/NCT02849496","fetchedAt":"2026-10-10T20:54:22.886389Z","studySha256":"1e19d8b1e98b08f5acd968de998a36e31958a79c2104d6238cffec83ecbfe068","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-28","leadSponsor":"National Cancer Institute (NCI)","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":89,"enrolmentType":"ACTUAL","siteCount":58,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2017-03-30","startedType":"actual","enrolled":89,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02849496/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}